Novartis buys Takeda’s dry eye drug for $3.4 bln

Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd’s dry eye drug Xiidra for an upfront payment of $3.4 billion to expand its portfolio of eye care medicines.

The deal includes potential milestone payments of up to $1.9 billion and is expected to close in the second half of 2019.



Related Topics and Keywords

Subscribe to our FREE newsletter

We will not sell or give your information to a third party. See our Privacy Policy